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OBJECTIVE — Most diabetic patients with impaired renal function have a urinary albumin
excretion rate in the normal range. In these patients, the etiology of renal impairment is unclear,
and it is also unclear whether this nonalbumunuric renal impairment is unique to diabetes.
RESEARCH DESIGN AND METHODS — In this study, we examined the frequency
and predictors of nonalbumunuric renal impairment (estimated glomerular ﬁltration rate
[eGFR] 60 ml/min per 1.73 m
2) in a nationally representative cohort of 3,893 patients with
type 2 diabetes and compared our ﬁndings with rates observed in the general population from
the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) survey (n  11,247).
RESULTS — Ofthe23.1%ofindividualswithtype2diabeteswhohadeGFR60ml/minper
1.73 m
2 (95% CI 21.8–24.5%), more than half (55%) had a urinary albumin excretion rate that
was persistently in the normal range. This rate of renal impairment was predictably higher than
that observed in the general population (adjusted odds ratio 1.3, 95% CI 1.1–1.5, P  0.01) but
was solely due to chronic kidney disease associated with albuminuria. In contrast, renal impair-
ment in the absence of albuminuria was less common in those with diabetes than in the general
population, independent of sex, ethnicity, and duration of diabetes (0.6, 0.5–0.7, P  0.001).
CONCLUSIONS — Nonalbuminuric renal impairment is not more common in those with
diabetes. However, its impact may be more signiﬁcant. New studies are required to address the
pathogenesis, prevention, and treatment of nonalbuminuric renal disease.
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S
creening for renal impairment is
nowrecommendedaspartofthean-
nual cycle of care for individuals
with type 2 diabetes (1,2). Most of those
identiﬁed as having an estimated glomer-
ular ﬁltration rate (eGFR) 60 ml/min
per 1.73 m
2 have a urinary albumin ex-
cretion rate in the normal range (3,4). It
has been suggested that the common
ﬁnding of nonalbuminuric renal impair-
ment is diabetic kidney disease masked
by blockers of the renin-angiotensin
system as well as aggressive antihyperten-
sive and lipid-lowering therapies (5). Al-
ternative explanations include selective
parenchymal damage associated with di-
abetes (6), superimposed nondiabetic
kidney disease, intrarenal vascular dis-
ease (7), or accelerated aging of the kid-
ney,eitheraloneorincombination(5).In
this study, we examine the frequency and
predictors of nonalbumunuric renal im-
pairment in a large nationally representa-
tive cohort of patients with type 2
diabetes (3,8) and compare them with
data observed in the age-, sex-, and eth-
nicity-matched general population (9).
RESEARCH DESIGN AND
METHODS— TheNationalEvaluation
of the Frequency of Renal Impairment
cO-existing with NIDDM (NEFRON)
study was an incident-driven survey of
patients with type 2 diabetes in the pri-
mary care setting. Investigator selection
and its representation of practitioners in
Australia is described elsewhere (3,8). In
brief,500randomlyselectedinvestigators
were requested to provide data on 10–15
consecutively presenting adult patients
with established type 2 diabetes. This
dataset cross-sectionally captured demo-
graphic information, including age, sex,
ethnicity, history of diabetes complica-
tions, medication usage, and smoking
and relevant family history, together with
details of physical examination and re-
sultsfromthemostrecentbloodtestsand
laboratory urinalysis. No attempt was
made to standardize data or assessment
methodologies but rather the intention
was to reﬂect the raw results on which
practitioners based their assessment and
decisions about management.
The AusDiab Study
The Australian Diabetes, Obesity and
Lifestyle (AusDiab) Study was a national
population-based cross-sectional survey
undertaken to determine the prevalence
of diabetes, obesity, and other cardiovas-
cular disease risk factors in Australian
adults. The details of this study and sam-
ple selection have been described previ-
ously(9).Inbrief,arepresentativesample
of 11,247 adults was recruited from 42
randomly selected urban and nonurban
areas across Australia. All subjects at-
tended a local screening and completed a
series of questionnaires, physical exami-
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formation on indicators of kidney
function was available for 97.4% (n 
10,949 of 11,247) of participants from
the general population (AusDiab survey).
Plasma and urine creatinine concentra-
tions were determined centrally by the
modiﬁed kinetic Jaffe reaction using an
Olympus AU600 autoanalyzer. Spot
urine albumin concentrations were as-
sessedcentrallybyimmunonephelometry
with the Beckman array (Beckman/
Coulter, Sydney, Australia). A diagnosis
of diabetes was based on self-reported
physiciandiagnosisofdiabetesconﬁrmed
either by self-reported use of hypoglyce-
mic drugs or results from a 75-g oral glu-
cose tolerance test. Of the population-
based AusDiab cohort, 8% had diabetes,
and in approximately half of these indi-
viduals, diabetes was detected for the ﬁrst
time at baseline screening (designated
“newly diagnosed diabetes”).
Deﬁnitions used and statistical
methods
eGFR was determined using the standard
four-variable Modiﬁcation of Diet in Re-
nal Disease formula (10),
eGFR  186  serum creatinine 
1.154  age  0.230 
[1.212 if black] or 
[0.742 if female],
whichhasbeenshowntobeareliabletool
for the determination of impaired kidney
functioninAustralianpatientswithtype2
diabetes (11) and is automatically re-
ported to practitioners whenever a serum
creatinine test is requested (12). For the
purposes of analysis, patients were strati-
ﬁedaccordingtostandardKidneyDisease
Outcomes Quality Initiative guidelines,
such that individuals with an eGFR 60
ml/min per 1.73 m
2 were said to have re-
nal impairment (13). Albuminuria was
stratiﬁed according to International Dia-
betes Federation guidelines, such that
menwithaurinaryalbumin-to-creatinine
ratio 2.5 mg/mmol and women with a
ratio 3.5 mg/mmol were considered to
have normoalbuminuria (14). Risks for
an eGFR 60 ml/min per 1.73 m
2 with
and without normoalbuminuria were de-
termined by multivariate logistic regres-
sion analysis and expressed as odds ratios
(ORs), adjusting for age, sex, ethnicity,
andbodysurfacearea.Theassociationbe-
tween age and the frequency of renal im-
pairment was characterized using a
regression spline, adjusting for sex, eth-
nicity, and body surface area.
RESULTS
NEFRON patient characteristics
The NEFRON survey collected data from
3,893 individuals with type 2 diabetes pre-
senting consecutively to their general prac-
titioner. The clinical characteristics of these
patients were described previously (3,8). In
brief, half of all patients were male (52%),
withamedianageof66yearsandamedian
duration of diagnosed diabetes of 6 years;
82.5% of patients were white, 10.2% were
Asian, and 3.7% were identiﬁed as Indige-
nous Australians by their practitioners.
Frequency of renal impairment
In patients with type 2 diabetes present-
ing to their practitioner, 23.1% had an
eGFR 60 ml/min per 1.73 m
2 (95% CI
21.8–24.5%). The ﬁnding of an eGFR
60 ml/min per 1.73 m
2 was more com-
mon in diabetic women than in men (ad-
justed OR 1.8, 95% CI 1.5–2.3, P 
0.001) (Fig. 1). Men with diabetes were
more likely to have an eGFR 60 ml/min
per 1.73 m
2 (1.5, 1.2–1.9, P  0.001),
comparedwithnondiabeticmenfromthe
general population, after adjusting for
age, sex, ethnicity, and body surface area
(Fig. 2). In contrast, women with type 2
diabetes were as likely to have an eGFR
60 ml/min per 1.73 m
2 as women from
thegeneralpopulation(0.9,0.8–1.1,P
0.3). This ﬁnding was the same across all
age-groups (Fig. 2).
Frequency of nonalbuminuric renal
impairment
More than half (55%) of all diabetic
patients in the NEFRON survey with
an eGFR 60 ml/min per 1.73 m
2 had
normoalbuminuria on their most recent
urinalysis. Most (98%) of these patients
were also reported as being persistently
normoalbuminuric by their practitioner.
Nonalbuminuric renal impairment was sig-
niﬁcantly more common in women with
type 2 diabetes than in diabetic men and
entirely explained the sex difference in the
frequency of renal impairment (Fig. 1).
Compared with the general popula-
tion,thefrequencyofnonalbuminuricre-
nal impairment was less common overall
in both diabetic men and diabetic women
(men: adjusted OR 0.7, 95% CI 0.6–0.9,
P  0.03; women: 0.6, 0.5–0.7, P 
0.001) (Fig. 2), after adjusting for age,
sex,ethnicity,andbodysurfacearea.Sim-
ilarﬁndingswereobservedindiabeticpa-
tients from the population-based
AusDiabsurvey(0.7,0.5–0.9,P0.001)
with results comparable to those ob-
served in the clinic-based NEFRON co-
hort, even in individuals with newly
diagnosed diabetes (Fig. 3).
The frequency of (any) renal impair-
ment was positively associated with pa-
tientage(Fig.1).However,thelikelihood
of that renal impairment being associated
with normal urinary albumin excretion
was not signiﬁcantly modiﬁed in either
Figure 1—Age-associated increase in the probability of any renal impairment (——) and renal
impairment with albuminuria (– – –) in men (f) and women ( ) with type 2 diabetes from the
NEFRON study.
Nonalbuminuric chronic kidney disease in diabetes
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presence or absence of diabetes (Fig. 2).
Signiﬁcant ethnic differences were
seen in the presentation of renal impair-
ment in individuals with type 2 diabetes:
54% of all white patients and 54% of all
Asianpatientswithtype2diabetesandan
eGFR 60 ml/min per 1.73 m
2 had nor-
mal levels of albumin in their urine. In
contrast, fewer than 17% of diabetic indi-
viduals with an Indigenous background
and an eGFR 60 ml/min per 1.73 m
2
hadnormoalbuminuria.Similarly,20%
of Polynesian patients with an eGFR 60
ml/min per 1.73 m
2 had normal urinary
albumin excretion.
Frequency of renal impairment
associated with elevated
albuminuria
Type 2 diabetes was associated with an
increased frequency of albuminuric renal
impairment compared with that in the
nondiabeticgeneralpopulation(men:ad-
justed odds ratio 3.4, 95% CI 2.5–4.7;
women: 2.6, 1.9–3.5; both P  0.001)
after adjustment for age, sex, ethnicity,
and body surface area. Renal impairment
associated with elevated albuminuria was
also more common in the small number
of diabetic patients included in the Aus-
Diab survey (2.4, 2.0–2.7; P  0.001),
even in those with newly diagnosed dia-
betes (Fig. 3). The adjusted frequency of
albuminuric renal impairment was not
different between men and women with
type 2 diabetes (P  0.4) (Fig. 1), regard-
less of ethnicity. This ﬁnding was consis-
tent with the similar frequency of
albuminuria seen in men and women
with an eGFR 60 ml/min per 1.73 m
2
(sex difference P  0.1).
Impaired glucose tolerance in the
general population and renal
impairment
Many adults in the Australian general
population have impaired glucose toler-
ance and/or elevated fasting glucose, par-
ticularly as they reach advanced age (15).
To explore whether this factor contrib-
uted to the ﬁndings detailed above, all
nondiabetic individuals within the Aus-
Diab cohort were further stratiﬁed on the
basis of an oral glucose tolerance test.
However, after adjustment for age, eth-
nicity, body surface area, and sex, neither
impaired glucose tolerance nor elevated
fasting glucose was associated with any
signiﬁcant change in the frequency of re-
nal impairment, with or without albu-
minuria (Fig. 3).
Renal impairment and comorbid
disease in type 2 diabetes
Diabetic patients with an eGFR 60 ml/
min per 1.73 m
2 and albuminuria were
more likely to have a history of hyperten-
sion, retinopathy, macrovascular disease,
or a ﬁrst-degree relative with chronic kid-
neydiseasethandiabeticindividualswith
aneGFR60ml/minper1.73m
2(allP
0.05).Thisdifferencewasnotobservedin
individuals with nonalbuminuric renal
impairment, after adjustment for con-
founding factors (Table 1). However, in
individuals with an eGFR 60 ml/min
per 1.73 m
2, both with and without albu-
minuria, rates of visual impairment, atrial
ﬁbrillation, and heart failure were signiﬁ-
cantly higher than those of diabetic indi-
viduals with an eGFR 60 ml/min per
1.73 m
2 (Table 1).
Practitioner perceptions of renal
impairment in type 2 diabetes
For all individuals with an eGFR 60 ml/
minper1.73m
2,thosewithnonalbumin-
Figure 2—Age-associated increase in the probability of any renal impairment (——) and non-
albuminuricrenalimpairment(– – –)inmen(A)andwomen(B)withtype2diabetes(f,  )and
in the general population ( ,   ).
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be identiﬁed by their general practitioner
as having (any) impaired kidney function
(62%) or “moderate to severe renal im-
pairment”(26%)thanthosewithaneGFR
60 ml/min per 1.73 m
2 and elevated
albuminuria (83 and 50%, respectively,
P0.001).Inaddition,patientswithnon-
albuminuric renal impairment were less
likely to have had their choice of drug
type or drug dose adjusted compared
with individuals with an eGFR 60 ml/
min per 1.73 m
2 and elevated albumin-
uria (both P  0.01).
CONCLUSIONS — Recent studies
have highlighted the large numbers of di-
abetic individuals with an eGFR 60 ml/
minper1.73m
2withoutelevatedurinary
albuminexcretion(so-callednonalbumu-
nuric renal impairment) (3–7,16). Al-
though many explanations have been
offered for this ﬁnding, the general pop-
ulation has similar or greater frequency of
nonalbuminuric renal impairment after
adjustmentforage,sex,andotherfactors.
Because estimation of kidney function is
now widely recommended as part of rou-
tine screening in all individuals with type
2 diabetes (1,2), it is possible that nonal-
bumunuric renal impairment is being in-
creasingly identiﬁed as clinicians have
begun routinely estimating the GFR of
their patients. This does not imply that
thisconditionshouldbeignored.Because
the risks associated with renal impair-
mentareadditive,itsimpactmaybemore
signiﬁcant in those with diabetes. Indeed,
in individuals with diabetes, renal im-
pairment (in the presence or absence of
albuminuria) ampliﬁes the risk of com-
plications, including anemia (17), heart
failure (18), adverse drug reactions
(18), hypertension, and premature
mortality (16,19).
Thecause(s)ofnonalbuminuricrenal
impairment remain to be established. In
our study many individuals with diabetes
were treated with agents that are known
to reduce urinary albumin excretion, in-
cluding agents that block the renin-
angiotensin system and aggressive
antihypertensive and lipid-lowering ther-
apies. It is therefore likely that some of
those with nonalbuminuric renal impair-
ment may have had higher levels of uri-
nary albumin excretion if not for their
treatment (i.e., masking albuminuric re-
nal impairment). This possibility would
mean that nonalbuminuric renal impair-
ment is even less common in those with
diabetes compared with the general pop-
ulationthansuggestedbyourﬁgures.Itis
not possible to adjust for such treatment
effects due to confounding by indication,
eveninsubjectswithnewlydiagnoseddi-
abetes. Moreover, such data are represen-
tative of clinical practice, where most
patients receive multiple antiproteinuric
therapies, even before a diagnosis of dia-
betes is made.
The number of diabetic individuals
with nonalbuminuric renal impairment
may also be lower because those individ-
uals predisposed to (any) renal disease
develop albuminuric disease when diabe-
tes is superimposed and nonalbuminuric
disease in its absence. Certainly, the in-
herited susceptibility to diabetic ne-
phropathy is not speciﬁc to diabetic renal
disease, such that family members of
those with end-stage renal disease due to
diabetes have higher rates of nondiabetic
as well as diabetic renal disease (20).
Some of this association may reﬂect com-
mon risk factors such as hypertension,
dyslipidemia,impairedglucosetolerance,
and obesity.
The standard immunochemical uri-
nary albumin assays used in this study
detected immunoreactive albumin,
whereas high-performance liquid chro-
matography (HPLC) detects both immu-
noreactive and immunounreactive
albumin. We have previously demon-
strated in the AusDiab cohort that HPLC-
based assays result in 17.4% of patients
classiﬁed as normoalbuminuric by means
of standard assays being reclassiﬁed as
Figure 3—Adjusted risk of eGFR 60 ml/min per 1.73 m
2 (u) and eGFR 60 ml/min per 1.73 m
2 without and with albuminuria (  and f,
respectively), stratiﬁed according to glucose tolerance and the presence of diabetes, adjusted for age, sex, ethnicity, and body surface area (*multi-
variate P  0.01 vs. individuals with normal glucose tolerance).
Nonalbuminuric chronic kidney disease in diabetes
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diabetes (OR 3.7) (21). Although HPLC-
based tests were not performed on the
NEFRON cohort, if consistent, these data
would again suggest that there are even
fewer diabetic individuals with nor-
moalbuminuric renal impairment than
observed in the general population.
This study has a number of strengths
including a large unselected nationally
representative cohort of patients with
type2diabetespresentingtotheirgeneral
practitioner as well as those in the general
population. This large cohort has facili-
tated appropriate adjustment for age, sex,
ethnicity, and body size, factors that have
the potential to confound interpretation
of the relative prevalence of renal disease.
However, as a clinic-based, incident-
drivenstudy,NEFRONalsohasanumber
of limitations, being inherently (and de-
liberately) biased toward the kind of pa-
tients with diabetes who regularly see
their practitioner and the nonstandard-
izedlaboratoryresultspractitionersuseto
make their clinical decisions. Initial re-
cruitment of investigators was based on
interest in undertaking the study, al-
though every effort was made to ensure a
representative distribution of general
practicesaccordingtostate,regionalarea,
and metropolitan versus rural practice.
Selection bias in relation to participating
investigators and subsequently enrolled
diabeticpatientsalsocannotberuledout.
Nonetheless,theconsistencyoftheclinic-
based NEFRON ﬁndings with those ob-
served in the smaller number of diabetic
individuals in the population-based Aus-
Diab survey that used standardized data
suggests that our ﬁndings may be gener-
alizable to those with type 2 diabetes.
However, it should also be noted that our
ﬁndings may also be confounded by sur-
vival bias, such that high-risk individuals
will be increasingly underrepresented
due to drop out as levels of renal function
decline.
Record numbers of individuals with
type 2 diabetes are seeing doctors. From
our surveys, we can anticipate that more
than half of these individuals will also
present with chronic kidney disease (3).
Many will have an eGFR 60 ml/min per
Table 1—Clinical characteristics of patients with type 2 diabetes from the NEFRON study stratiﬁed according to the presence and absence of
renal impairment and albumin excretion rate
eGFR 60 ml/min
per 1.73 m
2
eGFR 60 ml/min per 1.73 m
2
Normoalbuminuria Microalbuminuria Macroalbuminuria
n 3,063 506 295 119
Age (years) 63  17 3  1* 74  1* 71  1*
Sex (% male) 55  13 6  2* 50  4* 57  5*
Diabetes duration (years) 8  19  1* 11  1* 12  1*
Caucasian (%) 81  19 1  2* 87  2* 74  4*
Indigenous Australian (%) 4  11  1* 4  1* 10  2*
Asian (%) 11  16  1* 6  1* 11  3*
Weight (kg) 86  18 1  1* 81  1* 82  2*
Height (cm) 166  1 164  1* 165  1* 166  1*
Smoking (% current) 11  15  1† 8  2‡ 13  3‡
Smoking (% ex) 32  12 9  23 5  22 7  4
A1C (%) 7.4  0.1 7.0  0.1† 7.3  0.1‡ 7.5  0.2‡
Fasting plasma glucose (mmol/l) 8.0  0.1 7.4  0.1† 7.8  0.1† 8.5  0.1†‡
Lipid-lowering therapy (%) 63  17 0  2† 74  3† 75  4†
LDL cholesterol (mmol/l) 2.5  0.1 2.4  0.1† 2.3  0.1† 2.2  0.1†
HDL cholesterol (mmol/l) 1.3  0.1 1.2  0.1 1.3  0.1 1.4  0.1
Triglycerides (mmol/l) 2.0  0.1 1.9  0.1 2.0  0.1 2.2  0.1
Systolic blood pressure (mmHg) 133  1 135  1† 134  1† 137  2†
Diastolic blood pressure (mmHg) 77  17 5  1† 75  1† 76  1†
Treatment for hypertension (%) 67  18 0  1† 86  1†‡ 89  2†‡
No. of antihypertensive agents 1.4  0.1 1.9  0.1† 2.2  0.1† 2.5  0.1†‡
Duration of hypertension (years) 10  11 4  1† 15  1† 14  2†
Renin-angiotensin system blockade (%) 67  18 0  1† 84  2† 88  3†
Calcium channel blocker (%) 24  12 9  2† 36  3†‡ 44  5†‡
Diuretic (%) 24  14 2  2† 44  3† 45  5†
Retinopathy (%) 8  11 0  11 7  2†‡ 25  4†‡
Visual impairment (%) 15  13 1  3† 38  4† 31  5†
Macrovascular disease (%) 28  14 1  2† 52  3†‡ 55  5†‡
Treatment for heart failure (%) 5  11 4  2† 19  2†‡ 19  4†‡
Atrial ﬁbrillation (%) 4  17  1† 14  2†‡ 8  2†
Anemia (%) 13  12 8  2† 44  3†‡ 49  5†‡
Family history of renal disease (%) 6  19  1† 9  2† 13  3†‡
History of urinary tract infection (%) 9  11 3  1† 16  2† 18  3†‡
Data are means  SEM. *Univariate P  0.01, included in multivariate adjustments. †P  0.05 vs. eGFR 60 ml/min per 1.73 m
2, adjusted for age, sex, duration
of diabetes, body surface area, and ethnicity. ‡P  0.05 vs. eGFR 60 ml/min per 1.73 m
2  normoalbuminuria, adjusted for age, sex, duration of diabetes, body
surface area, and ethnicity.
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2, at least half of whom will not
have albuminuria. Nonetheless, a re-
duced eGFR identiﬁes individuals at in-
creased risk of adverse events, and much
can be done to prevent these complications
onceidentiﬁed.Althoughmostrecentstud-
ies have justiﬁably focused on the preven-
tion of albuminuric kidney disease in
diabetes, our data raise the possibility that
the lesion leading to nonalbuminuric renal
impairment is partly preventable by multi-
factorial interventions that comprise stan-
dard diabetes care. Moreover, because
nonalbuminuric disease is the most com-
mon presentation of renal impairment, this
effect may be a major beneﬁt of such thera-
pies and one that may be overlooked by al-
buminuria-centric studies. New studies are
urgently required to address the pathogen-
esis, prevention, and treatment of nonalbu-
minuric renal impairment, which is, in
reality,themostcommoncauseofrenalim-
pairment in the western world.
Acknowledgments— The NEFRON study
was conducted as a collaboration between the
Baker Heart Research Institute, Kidney Health
Australia, and Servier Australia. It was uncon-
ditionally funded by Servier Australia. The
AusDiab study was supported by the Com-
monwealth Department of Health and Aged
Care; State Governments of Queensland,
South Australia, Tasmania, Western Australia,
andVictoriaandTerritoryHealthServices;the
Australian Kidney Foundation; Diabetes Aus-
tralia (Northern Territory); and the Interna-
tional Diabetes Institute. M.C.T. is supported
by the Bootle Award from Kidney Health Aus-
tralia and funding from the National Health
and Medical Research Council and the Juve-
nile Diabetes Research Foundation.
The AusDiab study was also supported by
Eli Lilly (Australia); Janssen-Cilag (Australia);
Abbott (formally Knoll) (Australia); Merck
Lipha s.a. Alphapharm; Merck Sharp &
Dohme (Australia); Pharmacia and Upjohn;
Roche Diagnostics; GlaxoSmithKline; Bio-Rad
Laboratories; HITECH Pathology; and Qantas
Airways. No other potential conﬂicts of inter-
est relevant to this article were reported.
References
1. Standards of medical care in diabetes—
2008. Diabetes Care 2008;31(Suppl.1):
S12–S54
2. Canadian Diabetes Association Clinical
Practice Guidelines Expert Committee.
Canadian Diabetes Association 2008 clin-
ical practice guidelines for the prevention
and management of diabetes in Canada.
Can J Diabetes 2008;32(Suppl.1):S1–
S201
3. Thomas MC, Weekes AJ, Broadley OJ,
Cooper ME, Mathew TH. The burden of
chronic kidney disease in Australian pa-
tients with type 2 diabetes (the NEFRON
study). Med J Aust 2006;185:140–144
4. Thomas MC, MacIsaac RJ, Tsalamandris
C, Molyneaux L, Goubina I, Fulcher G,
Yue D, Jerums G. The burden of anaemia
intype2diabetesandtheroleofnephrop-
athy:across-sectionalaudit.NephrolDial
Transplant 2004;19:1792–1797
5. MacIsaac RJ, Tsalamandris C, Panagioto-
poulos S, Smith TJ, McNeil KJ, Jerums G.
Nonalbuminuric renal insufﬁciency in
type 2 diabetes. Diabetes Care 2004;27:
195–200
6. Kramer HJ, Nguyen QD, Curhan G, Hsu
CY. Renal insufﬁciency in the absence
of albuminuria and retinopathy among
adults with type 2 diabetes mellitus.
JAMA 2003;289:3273–3277
7. MacIsaac RJ, Jerums G. Albuminuric and
non-albuminuric pathways to renal im-
pairmentindiabetes.MinervaEndocrinol
2005;30:161–177
8. Thomas MC, Weekes AJ, Broadley OJ,
Cooper ME. The assessment of kidney
function by general practitioners in Aus-
tralian patients with type 2 diabetes
(NEFRON-2). Med J Aust 2006;185:
259–262
9. Dunstan DW, Zimmet PZ, Welborn TA,
CameronAJ,ShawJ,deCourtenM,Jolley
D, McCarty DJ. The Australian Diabetes,
Obesity and Lifestyle Study (AusDiab)—
methods and response rates. Diabetes Res
Clin Pract 2002;57:119–129
10. Levey AS, Bosch JP, Lewis JB, Greene T,
Rogers N, Roth D. A more accurate
method to estimate glomerular ﬁltration
rate from serum creatinine: a new predic-
tion equation. Modiﬁcation of Diet in Re-
nalDiseaseStudyGroup.AnnInternMed
1999;130:461–470
11. MacIsaac RJ, Tsalamandris C, Thomas
MC, Premaratne E, Panagiotopoulos S,
Smith TJ, Poon A, Jenkins MA, Ratna ˙ike
SI, Power DA, Jerums G. Estimating glo-
merular ﬁltration rate in diabetes: a com-
parison of cystatin-C– and creatine-based
methods. Diabetologia 2006;49:1686–
1689
12. Mathew TH. Chronic kidney disease and
automatic reporting of estimated glomer-
ular ﬁltration rate: a position statement.
Med J Aust 2005;183:138–141
13. Levey AS, Coresh J, Balk E, Kausz AT,
Levin A, Steffes MW, Hogg RJ, Perrone
RD, Lau J, Eknoyan G. National Kidney
Foundation practice guidelines for chronic
kidney disease: evaluation, classiﬁcation,
and stratiﬁcation. Ann Intern Med 2003;
139:137–147
14. InternationalDiabetesFederationClinical
Guidelines Task Force. Global Guideline
forType2Diabetes.Brussels,International
Diabetes Federation, 2005
15. Barr EL, Zimmet PZ, Welborn TA, Jolley
D, Magliano DJ, Dunstan DW, Cameron
AJ, Dwyer T, Taylor HR, Tonkin AM,
Wong TY, McNeil J, Shaw JE. Risk of car-
diovascular and all-cause mortality in in-
dividualswithdiabetesmellitus,impaired
fasting glucose, and impaired glucose tol-
erance: the Australian Diabetes, Obesity,
and Lifestyle Study (AusDiab). Circula-
tion 2007;116:151–157
16. So WY, Kong AP, Ma RC, Ozaki R, Szeto
CC, Chan NN, Ng V, Ho CS, Lam CW,
Chow CC, Cockram CS, Chan JC, Tong
PC.Glomerularﬁltrationrate,cardiorenal
endpoints,andall-causemortalityintype
2 diabetic patients. Diabetes Care 2006;
29:2046–2052
17. Thomas MC. Anemia in diabetes: marker
ormediatorofmicrovasculardisease?Nat
Clin Pract Nephrol 2007;3:20–30
18. Ekundayo OJ, Muchimba M, Aban IB,
Ritchie C, Campbell RC, Ahmed A. Mul-
timorbidity due to diabetes mellitus and
chronic kidney disease and outcomes in
chronic heart failure. Am J Cardiol 2009;
103:88–92
19. McCullough PA, Li S, Jurkovitz CT,
Stevens L, Collins AJ, Chen SC, Norris
KC,McFarlaneS,JohnsonB,ShlipakMG,
ObialoCI,BrownWW,VassalottiJ,Wha-
ley-Connell AT, Brenner RM, Bakris GL.
Chronic kidney disease, prevalence of
premature cardiovascular disease, and re-
lationship to short-term mortality. Am
Heart J 2008;156:277–283
20. Thompson CF, Simmons D, Collins JF,
Cecil A. Predisposition to nephropathy in
Polynesians is associated with family his-
tory of renal disease, not diabetes melli-
tus. Diabet Med 2001;18:40–46
21. PolkinghorneKR,SuQ,ChadbanSJ,Shaw
JE,ZimmetPZ,AtkinsRC.Populationprev-
alence of albuminuria in the Australian Di-
abetes, Obesity, and Lifestyle (AusDiab)
study: immunonephelometry compared
with high-performance liquid chromatog-
raphy. Am J Kidney Dis 2006;47:604–613
Nonalbuminuric chronic kidney disease in diabetes
1502 DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009